Compare VanEck Semiconductor ETF (SMH) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Semiconductor ETF vs Viatris Inc — how do they compare? VanEck Semiconductor ETF trades at $569.25, while Viatris Inc trades at $16.45 (market cap $18.95B). The key difference: Viatris Inc pays a 2.91% dividend while VanEck Semiconductor ETF pays none, and Viatris Inc is trading nearer its 52-week high, VanEck Semiconductor ETF nearer its low. Which is the better fit depends on your goals.
| SMH | VTRS | |
|---|---|---|
52-Week High | $668.91 | $17.86 |
52-Week Low | $300.83 | $9.49 |
Market Cap | — | $18.95B |
Sector | — | Health |
Enterprise Value | — | $31.07B |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMH trades at $573.73, up 1.19% with a bullish technical outlook supported by moving averages and positive momentum indicators. The semiconductor ETF benefits from strong AI infrastructure demand, with recent NVIDIA earnings and industry expansion driving investor interest. Institutional activity shows continued accumulation, including a $678,000 position by Greenland Capital Management.
Outlook remains positive given AI-driven semiconductor demand, though risks include potential tariff impacts and market volatility. The ETF's diversified exposure to chip leaders offers growth potential while mitigating single-stock risk, supported by Wall Street's constructive stance on the sector's long-term prospects.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
